Related Experiment Video
Updated: Apr 14, 2026
06:04
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
1.7K
A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk
Icilma V Fergus1, Kenneth L Connell, Keith C Ferdinand
1Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA, icilma.fergus@mountsinai.org.
Current Cardiology Reports
|April 23, 2015
Summary
Nebivolol, a beta-blocker, improves blood pressure and glucose control by increasing nitric oxide. This may benefit populations with nitric oxide deficiency, like Black individuals, in managing cardiometabolic risk.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Diseases
Background:
- Cardiometabolic risk factors contribute to atherosclerosis, myocardial infarction, and stroke.
- Beta-blockers are used for hypertension and cardiovascular diseases, with vasodilators offering metabolic benefits.
- Nitric oxide (NO) deficiency is implicated in cardiometabolic risk, particularly in certain populations.
Purpose of the Study:
- To evaluate the role of nebivolol, a third-generation beta-blocker, in managing cardiometabolic risk.
- To investigate nebivolol's mechanism of increasing nitric oxide (NO) bioavailability.
- To assess nebivolol's efficacy in blood pressure and glucose homeostasis, especially in NO-deficient populations.
Main Methods:
- Review of existing literature on beta-blockers, nebivolol, and nitric oxide.
- Analysis of nebivolol's vasodilatory properties and NO-boosting effects.
- Examination of clinical outcomes related to blood pressure and glucose metabolism.
Main Results:
- Nebivolol increases nitric oxide (NO) bioavailability.
- Vasodilating beta-blockers show benefits in blood pressure control and metabolic parameters.
- Nebivolol's NO-enhancing properties may be crucial for NO-deficient populations, including Black individuals.
Conclusions:
- Nebivolol demonstrates potential in improving cardiometabolic risk factors through NO enhancement.
- The drug may offer specific advantages for blood pressure and glucose regulation in populations with NO deficiency.
- Further research is warranted to confirm nebivolol's benefits in diverse populations at risk for cardiovascular events.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
2.0K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K